Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1216516227
rs1216516227
0.010 GeneticVariation BEFREE Initial screening revealed pathogenic variants in known cancer genes, including <i>BARD1</i>:p.Trp91* detected in a cancer-free individual, and <i>MEN1</i>:p.Glu260Lys detected in a BC patient. 31681433

2019

dbSNP: rs1799967
rs1799967
0.010 GeneticVariation BEFREE We found that two polymorphic variants, rs1799967 (BRCA1) and rs4987117 (BRCA2), were strongly associated with the risk of BC. 30611917

2019

dbSNP: rs80356932
rs80356932
0.010 GeneticVariation BEFREE Here we show that BRCA1 and BRCA2 variants are significantly associated with high breast cancer risk (BRCA1 rs80356932; Genotype T/T OR 8.66, 95% CI 3.16-23.71, p < 0.0001; Allele-T, OR 2.48, 95% CI 1.62-3.81, p < 0.0001 and BRCA2 rs80359182; Genotype C/C OR 4.32, 95% CI 1.95-9.53, p = 0.0001; Allele-C, OR 2.19, 95% CI 1.43-3.34, p = 0.0002). 30430339

2019

dbSNP: rs80357086
rs80357086
0.010 GeneticVariation BEFREE <b>Conclusions:</b> A high proportion of Japanese HBOC patients showed the <i>BRCA1</i> L63X mutation, and the clinical characteristics of breast cancer in patients with this mutation might differ from those in patients with other <i>BRCA1</i> or <i>BRCA2</i> mutations, in terms of the subtype and nuclear grade of the resultant cancer. 31143373

2019

dbSNP: rs431825395
rs431825395
0.010 GeneticVariation BEFREE The two missense variants <i>BRCA2</i>:c.91T >G (p.Trp31Gly) and <i>PALB2</i>:c.3262C >T (p.Pro1088Ser) were detected in two breast cancer probands originally ascertained at Breast Cancer Units of Institutes located in Milan and Bergamo (Northern Italy), respectively. 30410870

2018

dbSNP: rs786202998
rs786202998
0.010 GeneticVariation BEFREE Our study suggests that RNASEL:p.Glu265* may be a genetic modifier of risk for early-onset breast cancer predisposition in carriers of high-risk mutations. 29422015

2018

dbSNP: rs80357164
rs80357164
0.010 GeneticVariation BEFREE In summary, the BRCA1 Cys39Gly</span> and CYP17A1 -34T>C genetic variations were associated with breast cancer risk. 29510000

2018

dbSNP: rs80357275
rs80357275
0.010 GeneticVariation BEFREE ZNF350 L66P variant modifies the risk of breast cancer not only by itself but also in a gene-environment interaction manner with age, age at menarche, menopause status, or estrogen receptor status. 29653063

2018

dbSNP: rs80357641
rs80357641
0.010 GeneticVariation BEFREE It was found that ZNF350 rs2278420 (L66P) and rs2278415 (S501R) missense genetic variants are in complete linkage disequilibrium and have a significant impact on inter-individual susceptibility to breast cancer. 29653063

2018

dbSNP: rs1060502346
rs1060502346
0.010 GeneticVariation BEFREE Our findings establish L35P as the first pathogenic missense mutation in PALB2 and directly demonstrate the requirement of the PALB2-BRCA1 interaction for breast cancer suppression. 28319063

2017

dbSNP: rs273898682
rs273898682
0.010 GeneticVariation BEFREE Our study also suggests that BRCA1 p.Arg762Ser may be associated with increased risk of breast cancer but other methods or larger studies are required to determine a more precise estimate of breast cancer risk. 28222693

2017

dbSNP: rs786203319
rs786203319
0.010 GeneticVariation BEFREE Our findings establish L35P as the first pathogenic missense mutation in PALB2 and directly demonstrate the requirement of the PALB2-BRCA1 interaction for breast cancer suppression. 28319063

2017

dbSNP: rs799923
rs799923
0.010 GeneticVariation BEFREE In addition, we found four low-frequency variants (rs8176085, rs799923, rs8176173 and rs8176258) in the BRCA1 gene, one common variant in the CHEK2 gene (rs9620817), and one common variant in the PALB2 gene (rs13330119) associated with breast cancer risk at P < 0.01. 28419251

2017

dbSNP: rs80357750
rs80357750
0.010 GeneticVariation BEFREE Our findings establish L35P as the first pathogenic missense mutation in PALB2 and directly demonstrate the requirement of the PALB2-BRCA1 interaction for breast cancer suppression. 28319063

2017

dbSNP: rs8176173
rs8176173
0.010 GeneticVariation BEFREE In addition, we found four low-frequency variants (rs8176085, rs799923, rs8176173 and rs8176258) in the BRCA1 gene, one common variant in the CHEK2 gene (rs9620817), and one common variant in the PALB2 gene (rs13330119) associated with breast cancer risk at P < 0.01. 28419251

2017

dbSNP: rs8176258
rs8176258
0.010 GeneticVariation BEFREE In addition, we found four low-frequency variants (rs8176085, rs799923, rs8176173 and rs8176258) in the BRCA1 gene, one common variant in the CHEK2 gene (rs9620817), and one common variant in the PALB2 gene (rs13330119) associated with breast cancer risk at P < 0.01. 28419251

2017

dbSNP: rs886039920
rs886039920
0.010 GeneticVariation BEFREE Our findings establish L35P as the first pathogenic missense mutation in PALB2 and directly demonstrate the requirement of the PALB2-BRCA1 interaction for breast cancer suppression. 28319063

2017

dbSNP: rs16940
rs16940
0.010 GeneticVariation BEFREE The frequency of the polymorphism c.2311T>C was significantly higher in patients of the group BC+Her+Exp than in healthy women, and of the polymorphism 5382insC in BC+Her+Exp compared to all other groups. 27644661

2016

dbSNP: rs397507242
rs397507242
0.010 GeneticVariation BEFREE This report describes two breast cancer (BC) patients carrying BRCA1 L1705P and W1837X germ-line mutations, respectively. 26951538

2016

dbSNP: rs80356914
rs80356914
0.010 GeneticVariation BEFREE This report describes two breast cancer (BC) patients carrying BRCA1 L1705P and W1837X germ-line mutations, respectively. 26951538

2016

dbSNP: rs80357307
rs80357307
0.010 GeneticVariation BEFREE This report describes two breast cancer (BC) patients carrying BRCA1 L1705P and W1837X germ-line mutations, respectively. 26951538

2016

dbSNP: rs8176318
rs8176318
0.010 GeneticVariation BEFREE Gene-reproductive factors interactions analysis revealed that rs15869 together with age at menarche and number of pregnancy could increase the risk of BC by 2.39-fold and TT genotype (OR 0.316; 95% CI 0.130-0.767) of rs8176318 had a significant association with progesterone receptor status in BC patients. 27807724

2016

dbSNP: rs28897680
rs28897680
0.010 GeneticVariation BEFREE Mutational analysis of PALB2 gene revealed the novel mutation c.1919C>A (p.S640X) in a 29 years old woman with breast cancer. 25666743

2015

dbSNP: rs777515082
rs777515082
0.010 GeneticVariation BEFREE Heterozygosity for p.I171</span>V</span> was found in 4/235 patients with breast cancer and 3/281 individuals in the control group. 25712764

2015

dbSNP: rs786203965
rs786203965
0.010 GeneticVariation BEFREE Mutational analysis of PALB2 gene revealed the novel mutation c.1919C>A (p.S640X) in a 29 years old woman with breast cancer. 25666743

2015